NCT06937411

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants

A Phase I, Randomized, Double-Blinded, Placebo-Controlled, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Ascending Doses of DC-853 in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 88 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy participants. Participation could last up to 7 weeks

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY4100511	Administered orally

Timeline

• Start date: 2023-02-13
• Primary completion: 2023-10-30
• Completion: 2023-10-30
• First posted: 2025-04-22
• Last updated: 2025-04-22

Locations

1 site across 1 country: United Kingdom